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Drugs that inhibit the sodium–glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure
in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin
and dapagliflozin decreased the risk of serious new-onset heart failure events by ≈30%. In addition, in the EMPA-REG OUTCOME trial,
empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart
failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as
diuretics or anti-hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality
in patients with established heart failure, including those without diabetes. The EMPEROR-Reduced trial is enrolling ≈3600 patients with
heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being
randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin–angiotensin
system and neprilysin, beta-blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time-to-first event analysis
of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin
on renal function, cardiovascular death, all-cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic
peptide levels to the baseline ejection fraction, the trial will preferentially enrol high-risk patients. A large proportion of the participants is
expected to have an ejection fraction < 30%, and the estimated annual event rate is expected to be at least 15%. The EMPEROR-Reduced
trial is well-positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established
benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction.
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In patients with type 2 diabetes, drugs that inhibit the
sodium–glucose co-transporter 2 (SGLT2) have been shown to
reduce the risk of hospitalizations for heart failure.1–3 In popula-
tions that largely did not have heart failure at the time of enrolment,
empagliflozin, canagliflozin and dapagliflozin reduced the risk of
serious new-onset heart failure events by ≈30%.3–7 In addition, in
the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of
cardiovascular death, and this benefit was related to a reduced risk
of pump failure and sudden deaths, the two most common modes
of death among patients with heart failure.1,2,4 In none of the three
trials could the benefits of SGLT2 inhibitors on the development of
heart failure be explained by the effects of these drugs on glycaemic
control.1–3
These intriguing observations have raised important questions.
SGLT2 inhibitors may prevent the onset of heart failure in high-risk
patients, but can these drugs treat heart failure in those with
an established diagnosis? If the benefits of SGLT2 inhibitors on
heart failure are unrelated to their actions on blood glucose, could
these drugs exert favourable effects in patients who have heart
failure but who do not have diabetes? Would such benefits be
seen in those who are already receiving appropriate drug treat-
ments for heart failure? The answers to these questions have
important implications for the treatment of the millions of people
who have heart failure who remain at considerable risk of mor-
bidity and mortality despite optimal treatment with angiotensin
receptor–neprilysin inhibitors, beta-blockers and mineralocorti-
coid receptor antagonists.8,9
To address these questions, we are evaluating the effects of
empagliflozin in two large-scale clinical trials, one focused on
patients with a preserved ejection fraction (EMPEROR-Preserved,
NCT03057951) and the other focused on patients with a reduced
ejection fraction (EMPEROR-Reduced, NCT03057977). The two
trials, taken together, constitute the EMPEROR Program. This
paper describes the intent and design of the EMPEROR-Reduced
study.
Trial structure and oversight
The EMPEROR-Reduced trial is a phase III international, multicen-
tre, randomized, double-blind, parallel-group, placebo-controlled
trial that is evaluating the effects of empagliflozin on the mor-
bidity and mortality of patients with established heart failure
with a reduced ejection fraction (HFrEF), with or without type
2 diabetes. The trial is being conducted in accordance with
the principles of the Declaration of Helsinki and the Interna-
tional Conference on Harmonization Good Clinical Practice guide-
lines. The conduct of the study is approved by an institutional
review board for each participating centre, and all participants
provide written informed consent before study entry. The reg-
istration identifier on Clinicaltrials.gov is NCT03057977. The
sponsors of the trial are Boehringer Ingelheim and Eli Lilly and
Company.
The trial was designed by the Executive Committee, whose
members include academic investigators as well as representatives
of Boehringer Ingelheim. The Executive Committee was responsi-
ble for the development of the study protocol, and has scientific ..
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.. oversight on the development of the case report forms and the
statistical plan. In addition, the Executive Committee is oversee-
ing the pace of recruitment, the appropriateness of the patients
being enrolled, and the quality and thoroughness of follow-up. The
decisions and recommendations of the Executive Committee are
reached through joint collaboration and by consensus. National
leaders from key countries play a major regional role in encour-
aging recruitment and maintaining the commitment and dedication
of investigators. An Endpoint Adjudication Committee is evaluating
all reported and potential clinical events in a manner blinded to the
treatment assignment, and these will be judged to have met (or not
met) pre-specified criteria for a pre-specified endpoint or safety
event. An independent Data Monitoring Committee is responsible
for ongoing evaluation of the data that accrue during the course of
the trial and are charged with making recommendations about con-
tinuation or termination of the trial. At a planned interim analysis,
the Data Monitoring Committee may recommend to stop the trial
for overwhelming efficacy, which will be guided by pre-specified
stopping boundaries. The members of these Committees are listed
in the Appendix .
Study patients
Participants in the EMPEROR-Reduced trial are men or women,
aged ≥18 years who have had chronic heart failure (functional
class II, III or IV) for at least 3 months and whose left ventric-
ular ejection fraction is ≤ 40% at its most recent assessment
prior to enrolment. Patients must be receiving all appropriate
treatments for heart failure (as available and tolerated), includ-
ing diuretics, inhibitors of the renin–angiotensin system and
neprilysin, beta-blockers, mineralocorticoid receptor antagonists;
the doses of these medications must be stable for at least 1 week
prior to screening and remain constant during the screening
period until randomization. When feasible, cardiac devices (e.g.
a cardioverter-defibrillator or cardiac resynchronization ther-
apy) are used in a manner consistent with local or international
guidelines.
The intent of the trial is to enrol patients with heart failure
whose expected event rate for the combined risk of cardiovas-
cular death and hospitalization for heart failure will be at least 15%
per year. To achieve this goal, the trial protocol requires that base-
line levels of N-terminal prohormone B-type natriuretic peptide
(NT-proBNP) will exceed pre-defined levels that will vary with
the ejection fraction, i.e. the closer the ejection fraction is to the
threshold value of 40%, the higher the qualifying value for circulating
level of NT–proBNP:
• If the ejection fraction is ≤ 30%, the level of NT-proBNP
will be ≥ 600 pg/mL in patients without atrial fibrillation and
≥1200 pg/mL in patients with atrial fibrillation.
• If the ejection fraction is 31–35%, the level of NT-proBNP
will be ≥1000 pg/mL in patients without atrial fibrillation and
≥ 2000 pg/mL in patients with atrial fibrillation.
• If the ejection fraction is 36–40%, the level of NT-proBNP
will be ≥ 2500 pg/mL in patients without atrial fibrillation and
≥ 5000 pg/mL in patients with atrial fibrillation.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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• If the ejection fraction is > 40% but the patient has been
hospitalized for heart failure within the 12months prior to
screening, the level of NT-proBNP will be ≥ 600 pg/mL in
patients without atrial fibrillation and ≥ 1200 pg/mL in patients
with atrial fibrillation.
The intent of these criteria is to minimize the recruitment of
patients with chronic HFrEF who are at low risk of death or
hospitalization.
Patients are excluded if (i) they have a cardiovascular disorder
or are receiving treatments that increase the unpredictability of
or may change the patients’ clinical course, independent of heart
failure; (ii) they have an untreated or undertreated cardiovascular
condition that might influence the course of heart failure or tolera-
bility of the study medications; (iii) they have a significant co-morbid
condition that might influence the clinical course, independent of
heart failure; or (iv) if they have any condition that might jeopar-
dize patient safety, limit the patients’ participation in the trial, or
undermine the interpretation of trial data. All exclusion criteria are
listed in Table 1.
Study visits and follow-up
Following a screening period lasting 4–28 days, patients who fulfil
all eligibility criteria will be randomized double-blind (in a 1:1
manner) to receive placebo or empagliflozin 10 mg daily, in addition
to their usual therapy for heart failure (Figure 1). The dose of
empagliflozin for this trial was selected based on the observed
reduction in the risk of cardiovascular death produced by 10 mg
daily in a large-scale trial in patients with type 2 diabetes.1
Randomization is performed by using a permuted block design
with a computer pseudo-random number generator and is strat-
ified by (i) geographical region (North America, Latin America,
Europe, Asia, other); (ii) diabetes status at screening; and (iii)
estimated glomerular filtration rate [eGFR by the Chronic Kid-
ney Disease-Epidemiology Collaboration (CKD-EPI) equation]
at screening < 60 or ≥ 60mL/min/1.73m2). It is expected that
approximately half of the patients will not have diabetes at the
time of their enrolment. Following randomization, all appropriate
treatments for heart failure or other medical conditions may be ini-
tiated, adjusted or altered at the clinical discretion of each patient’s
physician or healthcare provider according to each patient’s needs.
Patients will be evaluated periodically at pre-specified study
visits. This assessment will include a description of each patient’s
New York Heart Association functional class as well as reporting
of adverse events. Quality of life related to heart failure will
be evaluated using the Kansas City Cardiomyopathy Question-
naire at randomization, after 3, 8 and 12months of double-blind
treatment, and at the end of double-blind treatment. Vari-
ous biomarkers and end-organ functional assessments will
include (but not be restricted to) the periodic measurement
of glycated haemoglobin, NT-proBNP, renal function (includ-
ing eGFR and urinary albumin-to-creatinine ratio) and liver
function tests; blood samples are banked for future biomarker
analyses. ..
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.. Investigators are expected to meticulously document all relevant
clinical events that occur from the time of randomization until
the trial completion. All randomized patients will be followed for
the occurrence of pre-specified primary and secondary outcome
events for the entire duration of the trial, regardless of whether
the study participants are taking their study medications or are
fully compliant with study procedures.
Primary and secondary endpoints
The primary endpoint of the EMPEROR-Reduced trial is the
time-to-first-event analysis of the combined risk of adjudicated car-
diovascular death or adjudicated hospitalization for heart failure.
The primary analysis will be based on the intention-to-treat prin-
ciple and include all randomized patients — from day of random-
ization until the end of the planned treatment period — whether
or not they are continuing to receive the study medications.
During the trial close-out period, patients will return for an
end-of-treatment visit and will be followed for an additional 30 days
off treatment. Primary events occurring during this follow-up
period will not be included in the primary analysis of efficacy, but
will be included in a separate analysis.
Differences between the placebo and empagliflozin groups for
the primary endpoint will be assessed for statistical significance
using a Cox proportional hazards model, with pre-specified
covariates of age, gender, geographical region, diabetes status at
baseline, left ventricular ejection fraction, and eGFR at baseline.
Age, ejection fraction and eGFR will be included in the model as
continuous variables.
Secondary endpoints will be analysed in a stepwise hierarchi-
cal manner so as to preserve the overall type one error rate at
a study-wide level of 0.05 (two-sided). The first-listed secondary
endpoint is the occurrence of adjudicated hospitalizations for heart
failure (including first and recurrent events), which will be eval-
uated using a joint frailty model that includes the consideration
of cardiovascular death as a potential source of informative cen-
soring. If this endpoint is successfully achieved, the analysis will
proceed to the second-listed secondary endpoint, i.e. the analy-
sis of the slope of the change in eGFR (CKD-EPI) from baseline,
which will be evaluated by a random coefficient model allow-
ing for random intercept and random slope per patient. If the
trial is not stopped at interim, an alpha of 0.001 is assigned to
this analysis, and the remaining alpha is applied to a patient-level
meta-analysis, which will be prospectively carried out to evalu-
ate the effects of empagliflozin (as compared with placebo) in
the EMPEROR-Reduced and EMPEROR-Preserved trials combined.
The endpoints for this meta-analysis include a composite renal
endpoint, cardiovascular death, time to new onset of diabetes
in patients without diabetes, and all-cause mortality; these are
also designated as secondary endpoints in the individual trials. If
the null hypothesis is not rejected at any step in the process of
sequential analysis, subsequent hypothesis testing will be consid-
ered to be exploratory, and P-values will be considered to be
nominal. All safety analyses will be based on the treated set, which
consists of all patients who received at least one dose of the
trial medication.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Exclusion criteria
Cardiovascular diseases or treatments that increase the unpredictability of or change the patients’ clinical course, independent of heart failure
Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischaemia or new ischemic ECG changes), coronary artery
bypass graft surgery, or other major cardiovascular surgery, stroke or transient ischaemic attack in past 90 days
Heart transplant recipient, or listed for heart transplant. Currently implanted left ventricular assist device
Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular
dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy, or known pericardial
constriction
Diagnosis of peripartum cardiomyopathy or cardiomyopathy induced by chemotherapy within 12months
Any severe (obstructive or regurgitant) valvular heart disease expected to lead to surgery during the trial period
Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or mechanical support within 1 week of
screening and during the screening period prior to randomization
ICD or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device for 3 months
following screening
Untreated or undertreated cardiovascular conditions that might influence the course of heart failure or tolerability of the study medications
Atrial fibrillation or atrial flutter with a resting heart rate >110 b.p.m. documented by ECG at screening
Untreated ventricular arrhythmia with syncope in a patient without an ICD within 3 months prior to screening
Symptomatic bradycardia or second or third degree heart block without a pacemaker after adjustment of beta-blocker therapy, if appropriate
Systolic blood pressure ≥ 180mmHg at randomization. If systolic blood pressure is 151–179mmHg, the patient should be receiving ≥3
anti-hypertensive drugs
Symptomatic hypotension and/or a systolic blood pressure <100mmHg at screening or at randomization
Significant co-morbid conditions that might influence the clinical course, independent of heart failure
Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalization for exacerbation within 12months; significant
chronic pulmonary disease; or primary pulmonary arterial hypertension
Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal
at screening
Impaired renal function, defined as eGFR < 20mL/min/1.73m2 (CKD-EPI) or requiring dialysis at the time of screening
Haemoglobin < 9 g/dL at screening
Major surgery (major according to the investigator’s assessment) performed within 90 days prior to screening, or major scheduled elective
surgery (e.g. hip replacement) within 90 days after screening
Gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption
Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell
carcinoma of the skin, in situ carcinoma of uterine cervix, or low risk prostate cancer (patients with pre-treatment PSA<10 ng/mL, and biopsy
Gleason score of ≤ 6 and clinical stage T1c or T2a)
Presence of any other disease than heart failure with a life expectancy of <1 year (in the opinion of the investigator)
Any condition that might jeopardize patient safety, limit the patients’ participation in the trial, or undermine the interpretation of trial data
Current use or prior use of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12weeks prior to screening or randomization.
Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted
Known allergy or hypersensitivity to any SGLT2 inhibitors
History of ketoacidosis
Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the
trial
Currently enrolled in another investigational device or drug study or are less than 30 days since the completion of a trial of another investigational
device or drug study. Any patient receiving any investigational treatment other than the study medications for this trial
Chronic alcohol or drug abuse or any condition that, in the investigator’s opinion, will make the patient unlikely to fulfil the trial requirements or
complete the trial
Women who are pregnant or are nursing or who plan to become pregnant while in the trial
Any other clinical condition that would jeopardize patient safety while participating in this trial or may prevent the subject from adhering to the
trial protocol
CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; PSA, prostate-specific
antigen; SGLT, sodium–glucose co-transporter.
Sample size calculations and study
conduct
The trial will be carried out as an event-driven study and will con-
tinue until 841 adjudicated primary endpoint events have occurred, ..
..
..
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..
..
. unless the trial is stopped early following a recommendation of the
Data Monitoring Committee. This number of events is expected
to provide the ability to detect a 20% difference in relative risk
of a primary endpoint event (two-sided alpha = 0.05), with 90%
power. Based on the assumption of a ≈15% event rate per year
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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of up to 28 days
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Median follow-up ≈ 20 months
Figure 1 Design for the EMPEROR-Reduced trial.
in the placebo arm and a recruitment period of 18months and a
follow-up period of 20months, the protocol specified an original
target of 2850 patients, with the option of increasing the number of
randomized patients up to 4000 patients, if the accumulation of pri-
mary endpoint events over calendar time is slower than expected.
Based on ongoing monitoring of event accrual and the presentation
of the phenotype results from the DECLARE–TIMI 58 trial,10 it was
decided to set the number of randomized patients at approximately
3600 (1800 patients per treatment group). The target number of
patients was determined without any knowledge of any unblinded
trial data and prior to the planned formal interim analysis of efficacy
by the Data Monitoring Committee. Each patient will be followed
for a minimum of 6 months following randomization.
Following the accrual of at least 500 primary endpoint events,
the Data Monitoring Committee will carry out one pre-specified
interim efficacy analysis, and based on this analysis, it may recom-
mend early termination of the study if a critical P-value for a benefit
on empagliflozin is achieved for both the primary endpoint and for
the analysis of cardiovascular death alone. The critical P-value is
determined by a Hwang–Shih–De Cani alpha-spending function
with parameter gamma of −8, which at approximately 500 events
(60% of the total number of expected events) yields a one-sided
alpha level of 0.001.11
Discussion
The ongoing EMPEROR-Reduced trial is evaluating the effect of
SGLT2 inhibition with empagliflozin on the risk of cardiovascular
death or hospitalization for heart failure in patients with established
symptoms of heart failure that are accompanied by evidence
of systolic dysfunction (i.e. a left ventricular ejection fraction
≤ 40% and meaningfully increased levels of natriuretic peptides).
In contrast to previous completed trials with SGLT2 inhibitors,1–3
the EMPEROR-Reduced trial will fully characterize the phenotypic
characteristics of patients and will ensure that the efficacy of
empagliflozin is evaluated in patients already receiving all other
appropriate treatments for heart failure. Importantly, because the
reported benefits of SGLT2 inhibitors on heart failure do not ..
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.. appear to be related to their effects on glycaemic control,1,2 the
trial is enrolling patients with or without diabetes. It is expected
that the diabetic and non-diabetic subgroups will each be large
enough to explore the presence of a treatment-by-diabetic status
interaction if one exists. However, since the benefits of SGLT2
inhibitors in heart failure are not related to glucose-lowering and
have been observed in non-diabetic models of HFrEF,12 such an
interaction is not anticipated.
An important feature of the EMPEROR-Reduced trial is its focus
on the recruitment of patients who have moderate-to-severe heart
failure who are at particularly high risk of cardiovascular death
and a hospitalization for worsening heart failure. To achieve this
goal, we have specified eligibility thresholds for entry levels of
NT-proBNP that are more stringent than any other prior or
ongoing heart failure trial. Each patient who is enrolled in the
EMPEROR-Reduced study is expected to be at particularly high
risk, because they exhibit marked decreases in ejection fraction
and/or marked increases in circulating levels of natriuretic pep-
tides and/or have had a recent hospitalization for heart failure; most
patients are expected to fulfil more than one of these enrichment
criteria. As a result, the trial is expected to recruit patients with a
greater severity of heart failure than those who are being enrolled
in another large-scale heart failure outcomes trials with the SGLT2
inhibitor, dapagliflozin (DAPA-HF).13 The enrolment of lower-risk
patients with milder degrees of heart failure likely explains why
the DAPA-HF trial is designed to be larger in size (approximately
4700 patients) and why an urgent visit for worsening heart fail-
ure (but without the need for hospitalization) is included as a
component of the primary endpoint in that study. As a result of
the implementation of our enrichment criteria, these additional
design features of DAPA-HF were unnecessary in the design of the
EMPEROR-Reduced trial.
In addition to the primary endpoint, the EMPEROR-Reduced
trial is designed to evaluate another important potential benefit
of SGLT2 inhibition, i.e. an effect of these drugs to slow the
rate of worsening of renal function.2,7 In patients with diabetes,
the action of SGLT2 inhibitors to promote sodium delivery to
the macula densa results (through tubuloglomerular feedback) in
afferent arteriolar vasoconstriction and, thereby, an amelioration
of glomerular hyperfiltration with lessening of the attendant risk
of renal parenchymal injury.14,15 Presumably as a result of the
activation of this mechanism, SGLT2 inhibitors have been shown
to slow the rate of progression of renal disease in patients with
type 2 diabetes, even after only 1–2 years of treatment;4 such
benefits are greater in magnitude and occur more rapidly with
SGLT2 inhibitors than with anti-diabetic drugs that have greater
anti-hyperglycaemic effects (e.g. glucagon-like peptide-1 receptor
agonists).14 However, the role of glomerular hyperfiltration in the
progression of renal dysfunction in patients with chronic heart
failure who do not have diabetes is not clear; the current trial may
provide important insights into this question.14,16,17
In addition to the trial’s primary and secondary endpoints, the
current programme is designed to determine if the favourable
effect of empagliflozin on cardiovascular death seen in a large-scale
trial in patients with type 2 diabetes1 will be replicated in
patients with chronic heart failure. Unless the magnitude of the
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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mortality benefit is striking, neither the EMPEROR-Reduced nor
the EMPEROR-Preserved trials (when each is considered alone)
are likely to be sufficiently large to adequately evaluate the pos-
sibility that empagliflozin might reduce the risk of cardiovascular
death. However, in the current programme, a hierarchical testing
procedure has been pre-specified that will combine the occur-
rence of cardiovascular deaths across the two heart failure trials
(EMPEROR-Reduced and EMPEROR-Preserved) on an individual
patient-level basis. If (as expected) the drug’s effect to reduce
the risk of heart failure hospitalization is confirmed, the com-
bined analysis of fatal events across the two trials should have
sufficient power to allow an unbiased assessment of the effect of
empagliflozin on cardiovascular mortality across the full spectrum
of patients with chronic heart failure, with or without left ven-
tricular systolic dysfunction. This approach is predicated on the
expectation that any drug-related reduction in mortality risk is not
meaningfully influenced by ejection fraction, and thus, heterogene-
ity across the trials will not affect the ability of the mortality data
to be pooled.
In a post hoc analysis of the DECLARE–TIMI 58 trial, the investi-
gators collected information on ejection fraction measured before
randomization in a subset of patients, in order to determine which
phenotype of heart failure [i.e. HFrEF or heart failure with a pre-
served ejection fraction (HFpEF)] was more likely to experience
a reduction in heart failure events with dapagliflozin.10 The inves-
tigators found that the magnitude of the reduction in the risk of
heart failure hospitalizations appeared to be greater in patients with
HFrEF than in HFpEF, and cardiovascular death was reduced only
in patients with HFrEF. The most striking benefit was observed in
patients with the lowest baseline left ventricular ejection fraction
(i.e. < 30%). Intriguingly, the EMPEROR-Reduced trial was origi-
nally designed to be enriched for these patients, long before the
phenotype results of DECLARE–TIMI 58 were known. However,
the findings with dapagliflozin must be interpreted cautiously since
these post hoc analyses are based on incomplete data that were
collected only in patients with type 2 diabetes.
If the EMPEROR-Reduced trial confirms a favourable effect on
empagliflozin on the study’s pre-specified primary and secondary
endpoints, the trial will not necessarily be able to discern the
relative contribution of diverse mechanisms to explain the
observed benefits. In patients with type 2 diabetes, treatment
with SGLT2 inhibitors causes a natriuresis and weight loss, and
the haemoconcentration produced by these drugs in earlier trials
suggests a meaningful contraction of plasma volume and interstitial
fluid which might be beneficial in patients with chronic heart
failure.1,18 However, such a mechanism is not likely to contribute
to benefits of the drug in chronic heart failure if our patients are
adequately treated with diuretics and if the dose of diuretics is
appropriately adjusted to the clinical needs of the patients during
the course of the trial. More importantly, intensification of diuretic
therapy has not led to a dramatic decrease in cardiovascular
mortality or sudden death in patients with heart failure.19
What mechanism(s) might then be responsible for such a strik-
ing cardioprotective effect of SGLT2 inhibitors in HFrEF? SGLT2
inhibitors increase fasting levels of ketone bodies, and thus, they
have been hypothesized to enhance the utilization of this efficient ..
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.. metabolic fuel in the failing heart.20–22 However, the findings of
experimental studies have provided inconsistent support for this
hypothesis.23–25 Instead, it has been proposed that SGLT2 inhibitors
may slow the course of cardiomyocyte injury and loss by inhibiting
the sodium–hydrogen exchanger-1 (NHE-1) in the myocardium,
whose overactivity may lead to increases in intracellular sodium and
calcium, which can impair cardiomyocyte function and viability.26–31
Interestingly, empagliflozin has also been shown to inhibit the
activation of Ca++/calmodulin-dependent kinase II, which con-
tributes to the activation of NHE-1 in the heart.32–34 The actions of
empagliflozin to prevent calcium overload may explain why the drug
prevents the time-dependent decline in systolic cardiac function
seen in experimental pressure overload-induced heart failure.35,36
Regardless of the mechanisms that might be in play, the
EMPEROR-Reduced trial is well-positioned to determine if the
addition of SGLT2 inhibitors could add meaningfully to current
approaches that have established benefits in the treatment of
chronic heart failure. The findings of the trial are likely to advance
both our understanding of the disease as well as our treatment
options.
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